Brief: Madrigal Pharmaceuticals Publishes Positive Results From Phase 3 Maestro-Nash Trial Of Rezdiffra
30/09/2024 13:15
Sept 30 (Reuters) - Madrigal Pharmaceuticals Inc
MDGL.O :
* MADRIGAL PHARMACEUTICALS ANNOUNCES PUBLICATION OF POSITIVE
HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE 3
MAESTRO-NASH TRIAL OF REZDIFFRA™ (RESMETIROM)
* MADRIGAL PHARMACEUTICALS INC - REZDIFFRA ACHIEVES PRIMARY
ENDPOINTS IN PHASE 3 TRIAL
* MADRIGAL PHARMACEUTICALS INC - REZDIFFRA SHOWS SIGNIFICANT
HRQL
IMPROVEMENT COMPARED TO PLACEBO
Source text for Eikon: urn:newsml:reuters.com:*:nGNX8gmB1Q
Further company coverage: MDGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)